Wang Lingling, Yang Jingru, Yang Li, Zhu Yun, Tang Xiaomin, Cao Xinyu, Kang Wenbo, Sun Haitao, Xie Zongyu
School of Medical Imaging, Bengbu Medical University, Bengbu, China.
Department of Radiology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Front Oncol. 2025 Jul 15;15:1544058. doi: 10.3389/fonc.2025.1544058. eCollection 2025.
To explore an MRI-based radiomics model for predicting the efficacy of neoadjuvant therapy (NAT) for breast cancer with HER2 overexpression.
A total of 133 patients with HER2 positive breast cancer who underwent neoadjuvant therapy were retrospectively enrolled and divided into pathological complete response (PCR) and non-PCR groups. The patients from two centers were split into a training group (n=68) and a test group (n=65). MRI sequences (fs-T2WI, DWI, DCE-MRI) were used to outline regions of interest (ROI). Optimal features were selected using f-classif function and LASSO regression, and a multi-parameter MRI radiomics score (Rad-score) was constructed via logistic regression. Clinical independent predictors were identified to build a clinical model, and a nomogram was developed by combining Rad-score with these predictors. Model performance was evaluated using AUC, DeLong test, calibration curves, and decision curve analysis (DCA).
In this study, multivariate analysis identified key predictive clinical factors for pCR, including Ki-67 increment index and tumor morphology. Additionally, a total of 3375 radiomics features were extracted, and 7 key features were selected for model construction. Compared with the image group model and clinical model, the nomogram model based on imaging group had the best predictive performance (training group AUC: 0.894, sensitivity 83.72%, specificity 84.00%, test group AUC: 0.878, sensitivity 88.64%, specificity 71.43%). The calibration and decision curve analyses confirmed its strong consistency and clinical utility compared to individual models.
The nomogram model based on multi-parameter MRI has a steady performance in predicting the efficacy of NAT in breast cancer patients with HER2 overexpression, which provides important guidance for clinical treatment and decision-making.
探索一种基于MRI的放射组学模型,用于预测HER2过表达乳腺癌新辅助治疗(NAT)的疗效。
回顾性纳入133例接受新辅助治疗的HER2阳性乳腺癌患者,分为病理完全缓解(PCR)组和非PCR组。来自两个中心的患者被分为训练组(n = 68)和测试组(n = 65)。使用MRI序列(脂肪抑制T2加权成像、扩散加权成像、动态对比增强MRI)勾勒感兴趣区域(ROI)。使用f分类函数和LASSO回归选择最佳特征,并通过逻辑回归构建多参数MRI放射组学评分(Rad-score)。确定临床独立预测因素以建立临床模型,并通过将Rad-score与这些预测因素相结合来制定列线图。使用曲线下面积(AUC)、德龙检验、校准曲线和决策曲线分析(DCA)评估模型性能。
本研究中,多因素分析确定了pCR的关键预测临床因素,包括Ki-67增殖指数和肿瘤形态。此外,共提取了3375个放射组学特征,并选择了7个关键特征用于模型构建。与影像组模型和临床模型相比,基于影像组的列线图模型具有最佳的预测性能(训练组AUC:0.894,灵敏度83.72%,特异度84.00%;测试组AUC:0.878,灵敏度88.64%,特异度71.43%)。校准和决策曲线分析证实,与单个模型相比,其具有更强的一致性和临床实用性。
基于多参数MRI的列线图模型在预测HER2过表达乳腺癌患者NAT疗效方面具有稳定的性能,为临床治疗和决策提供了重要指导。